Cel' : Provesti metaanaliz perspektivnyh issledovaniy, v kotoryh sravnivaetsya farmakogeneticheskiy sposob dozirovaniya antidepressantov i tradicionnyy.
antidepressants, pharmacogenetics, pharmacogenomics, meta-analysis, prospective study
1. Greden, JF, Parikh SV, Rothschild AJ, Thase ME, Dunlop BW, DeBattista C. Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: a large, patient-and rater-blinded, randomized, controlled study// Journal of psychiatric research. 2019. 59-67.
2. Bradley P, Shiekh M, Mehra V, Vrbicky K, Layle S, Olson MC. Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: a randomized clinical trial demonstrating clinical utility// Journal of psychiatric research. 2018. 100-107.
3. Hall-Flavin, DK, Winner JG, Allen JD, Carhart JM, Proctor B, Snyder KA. Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting// Pharmacogenetics and genomics. 2013. 535-548.
4. Pérez V, Salavert, A, Espadaler, J, Tuson, M, Saiz-Ruiz J, Sáez-Navarro C. Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial// BMC psychiatry. 2017. 1-13.
5. Singh AB. Improved antidepressant remission in major depression via a pharmacokinetic pathway polygene pharmacogenetic report// Clinical Psychopharmacology and Neuroscience. 2015. 150.
